Abstract
Drug resistance is a serious limitation to the effective treatment of a number of common malignancies. Thirty years of laboratory and clinical research have greatly defined the molecular alterations underlying many drug resistance processes in cancer. Based on this knowledge, strategies to overcome the impact of resistance and increase the efficacy of cancer treatment have been translated from laboratory models to clinical trials. This article reviews laboratory and, in particular, clinical attempts at drug resistance circumvention from early forays in the inhibition of cellular efflux pumpmediated drug resistance through to more selective circumvention agent strategies and into inhibition of the other important mechanisms which can allow cancer cells to survive therapy, such as apoptosis resistance. Despite some promising results to date, resistance inhibition strategies have largely failed due to poor understanding of the pharmacology, dynamics and complexity of the resistance phenotype. With the realisation that new molecularly-targeted agents can also be rendered ineffectual by the actions of resistance mechanisms, a major focus is once again emerging on identifying new strategies/pharmaceuticals which can augment the activity of the arsenal of more conventional cytotoxics and newer targeted anti-cancer drugs. Future tactical directions where old and new resistance strategies may merge to overcome this challenge are discussed.
Keywords: Resistance, resistance pharmacology, MDR, circumvention, apoptosis, pharmacokinetic resistance, pharmacodynamic resistance
Current Cancer Drug Targets
Title: A Review of Mechanisms of Circumvention and Modulation of Chemotherapeutic Drug Resistance
Volume: 9 Issue: 3
Author(s): R. O'Connor
Affiliation:
Keywords: Resistance, resistance pharmacology, MDR, circumvention, apoptosis, pharmacokinetic resistance, pharmacodynamic resistance
Abstract: Drug resistance is a serious limitation to the effective treatment of a number of common malignancies. Thirty years of laboratory and clinical research have greatly defined the molecular alterations underlying many drug resistance processes in cancer. Based on this knowledge, strategies to overcome the impact of resistance and increase the efficacy of cancer treatment have been translated from laboratory models to clinical trials. This article reviews laboratory and, in particular, clinical attempts at drug resistance circumvention from early forays in the inhibition of cellular efflux pumpmediated drug resistance through to more selective circumvention agent strategies and into inhibition of the other important mechanisms which can allow cancer cells to survive therapy, such as apoptosis resistance. Despite some promising results to date, resistance inhibition strategies have largely failed due to poor understanding of the pharmacology, dynamics and complexity of the resistance phenotype. With the realisation that new molecularly-targeted agents can also be rendered ineffectual by the actions of resistance mechanisms, a major focus is once again emerging on identifying new strategies/pharmaceuticals which can augment the activity of the arsenal of more conventional cytotoxics and newer targeted anti-cancer drugs. Future tactical directions where old and new resistance strategies may merge to overcome this challenge are discussed.
Export Options
About this article
Cite this article as:
O'Connor R., A Review of Mechanisms of Circumvention and Modulation of Chemotherapeutic Drug Resistance, Current Cancer Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/156800909788166583
DOI https://dx.doi.org/10.2174/156800909788166583 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IL-22 and Its Receptors, New Players in the Inflammatory Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Humanin Peptide Binds to Insulin-Like Growth Factor-Binding Protein 3 (IGFBP3) and Regulates Its Interaction with Importin-β
Protein & Peptide Letters One-Pot Synthesis of Alkyl 4-alkyl-2,8-dioxo-2H,8H-pyrano[2,3- f]chromene-10-carboxylates and Alkyl 2(E)-3-[(4-alkyl-2-oxo-2H-chromen- 7-yl)oxy]acrylates
Letters in Organic Chemistry Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Current Topics in Medicinal Chemistry Meet Our Regional Editor
MicroRNA Therapeutic Strategies to Target Multiple Kinases in Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Refractory Cough as a Remote Manifestation of Retroperitoneal Liposarcoma
Current Cancer Therapy Reviews Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Label-Free Cell Phenotypic Assays for Assessing Drug Polypharmacology
Current Pharmaceutical Design Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms
Current Cardiology Reviews Curcumin as an Adjuvant to Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Role of the Adenosinergic Pathway in Immunosuppression Mediated by Human Regulatory T Cells (Treg)
Current Medicinal Chemistry Antioxidant Activities of Retinoidal Benzimidazole Or Indole Derivatives in In Vitro Model Systems
Current Medicinal Chemistry Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Current Cancer Drug Targets Nuclear Architecture and Gene Expression in the Quest for Novel Therapeutics
Current Pharmaceutical Design The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story
Current Neuropharmacology Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics KF/Clinoptilolite Nanoparticles as a Heterogeneous Catalyst for Green Synthesis of pyrido[2,1-a]isoquinolines using Four-Component Reaction of Alkyl Bromides
Combinatorial Chemistry & High Throughput Screening